Chuck Sholtz
About Chuck Sholtz
Chuck Sholtz: Vice President, Intellectual Property
Chuck Sholtz currently holds the position of Vice President, Intellectual Property. His extensive background in intellectual property law and neuroscience underpins his leadership role. In his capacity as Vice President, he is responsible for overseeing IP strategy and ensuring the protection and management of intellectual property assets.
Chuck Sholtz Education and Expertise
Chuck Sholtz possesses a diverse and robust educational background. He earned B.S. and B.S.E. degrees from the University of Michigan, highlighting his early foundation in science and engineering. He furthered his studies with an M.A. from Yale University and completed a Ph.D. in Neuroscience at Stanford University. Additionally, he holds a J.D. from Santa Clara University School of Law, equipping him with the legal expertise necessary for his career in intellectual property.
Professional Background of Chuck Sholtz
Chuck Sholtz has a rich professional background in intellectual property and law. He spent 8 years at Amgen, where he served in various capacities including Neuroscience Therapeutic Area IP Team Lead. Subsequently, he served as Vice President, Intellectual Property at Coherus Biosciences. Prior to his current role, he was a Director at Genentech, leading a team of IP agents and attorneys.
Chuck Sholtz at Genentech
Chuck Sholtz was a Director at Genentech, where he led a team of intellectual property agents and attorneys. During his tenure, he played a pivotal role in the management and strategic oversight of Genentech's intellectual property assets. His leadership contributed to the protection and commercialization of the company's innovations.
Chuck Sholtz's Career at Amgen
At Amgen, Chuck Sholtz served as an IP attorney for 8 years. His roles included serving as the Neuroscience Therapeutic Area IP Team Lead. In this capacity, he managed IP strategy and protection for neuroscience-related therapeutics, leveraging his expertise in both law and neuroscience. His contributions were integral to safeguarding Amgen's intellectual property assets in the highly specialized field of neuroscience.